drugset / Trial / NCT06433531
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
Phase 1
Active not recruiting
9 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, single-group, open-label study to evaluate the safety and tolerability of TQH2929 injection at a dose of 900mg in adult subjects with active Generalized Pustular Psoriasis (GPP), and to preliminarily evaluate the efficacy.
Timeline
- Start
- 2024-06-19
- Primary completion
- 2025-07-08
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQH2929 | Monoclonal antibody | 900 mg | — |